Study of Repetitive Intestinal Lavage in Patients With EHEC Associated Hemorrhagic Colitis (EHEC-PEG)
Hemolytic Uremic Syndrome, Hemorrhagic Colitis, Intestinal Infectious Disease
About this trial
This is an interventional prevention trial for Hemolytic Uremic Syndrome focused on measuring EHEC, O104:H4, German, outbreak, polyethylene glycol, Bowel lavage
Eligibility Criteria
Inclusion Criteria:
- Proven EHEC O104:H4-infection
Presence of bloody diarrhoea + at least one of the following serological criteria:
- platelet count below 150x10³/ μl but greater than 100x10³/ μl, serum creatine above normal level for age (> 1.1 -1.3 mg/dl), Lactate dehydrogenase (LDH) > 300 IU/l, leukocytosis ( > 12x10³/ μl ) and elevated CRP (> 5mg/l), hemoglobin < 13.8 g/dL for male patients or < 12.1 g/dL for female patients, respectively or decrease in haptoglobin
Exclusion Criteria:
- Bloody diarrhoea due to others reasons than EHEC O104:H4 infection
- Thrombocytopenia < 100x10³/ μl.
- HUS, defined as platelet count below 100x10³/ μl, anaemia or decrease in haptoglobin and serum creatine above normal level for age
Sites / Locations
- 1Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
SOC-treatment
PEG-Solution, daily bowel lavage
Patients with EHEC associated bloody diarrhoea (n=12) receiving standard of care treatment, consisting of intravenous fluids (2-3 liters/daily), analgetics, including paracetamol and metamizol and metoclopramid, if required.
Patients with EHEC associated bloody diarrhoea (n=21)receiving SOC-treatment, consisting of i.v. fluids (2-3 liter/day), analgetics ( paracetamol and metamizol) or metoclopramid and orally administered polyethylene glycol-solution daily during the clinical course.